{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:58:58Z","timestamp":1791935938171,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45404-5","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:04:13Z","timestamp":1775898253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ranolazine as an adjunct to standard therapy for angina in myocardial bridging: a randomized clinical trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Alireza","family":"Abdi-Ardekani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1092-4206","authenticated-orcid":false,"given":"Nasim","family":"Kheirandish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Yaser","family":"Rahbarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7773-8806","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Arzhangzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Saem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Kamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1857-371X","authenticated-orcid":false,"given":"Helia","family":"Bazroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3200-3774","authenticated-orcid":false,"given":"Sana","family":"Neisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2483-4652","authenticated-orcid":false,"given":"Mitra","family":"Mojibpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Imani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Bazrafshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Bazrafshan Drissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"Suppl I","key":"45404_CR1","doi-asserted-by":"publisher","first-page":"I61","DOI":"10.1093\/eurheartjsupp\/suac075","volume":"24","author":"A Santucci","year":"2022","unstructured":"Santucci, A. et al. The myocardial bridge: incidence, diagnosis, and prognosis of a pathology of uncertain clinical significance. Eur. Heart J. Suppl. 24 (Suppl I), I61\u2013i67 (2022).","journal-title":"Eur. Heart J. Suppl."},{"issue":"4","key":"45404_CR2","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/1556-4029.13665","volume":"63","author":"S Hostiuc","year":"2018","unstructured":"Hostiuc, S. et al. Myocardial Bridging: A Meta-Analysis of Prevalence. J. Forensic Sci. 63 (4), 1176\u20131185 (2018).","journal-title":"J. Forensic Sci."},{"issue":"5","key":"45404_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ca.23697","volume":"34","author":"W Roberts","year":"2021","unstructured":"Roberts, W. et al. Myocardial bridges: A meta-analysis. Clin. Anat. 34 (5), 685\u2013709 (2021).","journal-title":"Clin. Anat."},{"key":"45404_CR4","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.5114\/pjr.2019.90370","volume":"84","author":"R Rajendran","year":"2019","unstructured":"Rajendran, R. & Hegde, M. The prevalence of myocardial bridging on multidetector computed tomography and its relation to coronary plaques. Pol. J. Radiol. 84, e478\u2013e483 (2019).","journal-title":"Pol. J. Radiol."},{"issue":"12","key":"45404_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1161\/CIRCULATIONAHA.114.012636","volume":"131","author":"BK Lee","year":"2015","unstructured":"Lee, B. K. et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation 131 (12), 1054\u20131060 (2015).","journal-title":"Circulation"},{"issue":"5","key":"45404_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/chd.12499","volume":"12","author":"IS Rogers","year":"2017","unstructured":"Rogers, I. S., Tremmel, J. A. & Schnittger, I. Myocardial bridges: Overview of diagnosis and management. Congenit Heart Dis. 12 (5), 619\u2013623 (2017).","journal-title":"Congenit Heart Dis."},{"issue":"22","key":"45404_CR7","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/j.jacc.2014.01.049","volume":"63","author":"MT Corban","year":"2014","unstructured":"Corban, M. T. et al. Myocardial bridging: contemporary understanding of pathophysiology with implications for diagnostic and therapeutic strategies. J. Am. Coll. Cardiol. 63 (22), 2346\u20132355 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"45404_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/0735-1097(96)00062-9","volume":"27","author":"ER Schwarz","year":"1996","unstructured":"Schwarz, E. R. et al. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. J. Am. Coll. Cardiol. 27 (7), 1637\u20131645 (1996).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"45404_CR9","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1161\/01.CIR.96.9.2905","volume":"96","author":"HG Klues","year":"1997","unstructured":"Klues, H. G. et al. Disturbed intracoronary hemodynamics in myocardial bridging: early normalization by intracoronary stent placement. Circulation 96 (9), 2905\u20132913 (1997).","journal-title":"Circulation"},{"issue":"8","key":"45404_CR10","first-page":"e43132","volume":"15","author":"EO Evbayekha","year":"2023","unstructured":"Evbayekha, E. O. et al. A Comprehensive Review of Myocardial Bridging: Exploring Diagnostic and Treatment Modalities. Cureus 15 (8), e43132 (2023).","journal-title":"Cureus"},{"issue":"3","key":"45404_CR11","doi-asserted-by":"publisher","first-page":"e003196","DOI":"10.1161\/JAHA.116.003196","volume":"5","author":"E Rayner-Hartley","year":"2016","unstructured":"Rayner-Hartley, E. & Sedlak, T. Ranolazine: A Contemporary Review. J. Am. Heart Assoc. 5 (3), e003196 (2016).","journal-title":"J. Am. Heart Assoc."},{"key":"45404_CR12","doi-asserted-by":"crossref","unstructured":"Al Batran, R. et al. The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity. JCI Insight, 4(1). (2019).","DOI":"10.1172\/jci.insight.124643"},{"issue":"1","key":"45404_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cjco.2020.09.005","volume":"3","author":"T Kofler","year":"2021","unstructured":"Kofler, T. et al. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction-A Systematic Review and Meta-analysis of Randomized Trials. CJC Open. 3 (1), 101\u2013108 (2021).","journal-title":"CJC Open."},{"issue":"3","key":"45404_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/circ.54.3.947585","volume":"54","author":"L Campeau","year":"1976","unstructured":"Campeau, L. Letter: Grading of angina pectoris. Circulation 54 (3), 522\u2013523 (1976).","journal-title":"Circulation"},{"key":"45404_CR15","first-page":"63","volume":"8","author":"D Chakrabarty","year":"2016","unstructured":"Chakrabarty, D. & Sarmah, B. Table Two-Digit Random Numbers. AryaBhatta J. Math. & Info. 8: 63\u201374. (2016).","journal-title":"Table Two-Digit Random Numbers"},{"key":"45404_CR16","unstructured":"Chow, S. C. et al. Sample Size Calculations in Clinical Research 3rd edn (Chapman and Hall\/CRC, 2017)."},{"issue":"8","key":"45404_CR17","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman, B. R. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43 (8), 1375\u20131382 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"45404_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/2047487314533217","volume":"22","author":"J Belsey","year":"2015","unstructured":"Belsey, J. et al. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 22 (7), 837\u2013848 (2015).","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"45404_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","volume":"169","author":"G Savarese","year":"2013","unstructured":"Savarese, G. et al. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int. J. Cardiol. 169 (4), 262\u2013270 (2013).","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"45404_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.amjcard.2013.11.070","volume":"113","author":"D Banon","year":"2014","unstructured":"Banon, D. et al. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials. Am. J. Cardiol. 113 (6), 1075\u20131082 (2014).","journal-title":"Am. J. Cardiol."},{"key":"45404_CR21","unstructured":"Salazar, C. A. et al. Ranolazine for stable angina pectori. Cochrane Database Syst. Rev., 2(2), Cd011747 (2017)."},{"issue":"6","key":"45404_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.carrev.2017.04.012","volume":"18","author":"B Ahmed","year":"2017","unstructured":"Ahmed, B. et al. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc. Revasc Med. 18 (6), 431\u2013435 (2017).","journal-title":"Cardiovasc. Revasc Med."},{"key":"45404_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2018.09.081","volume":"276","author":"CA Rambarat","year":"2019","unstructured":"Rambarat, C. A. et al. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women\u2019s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study. Int. J. Cardiol. 276, 8\u201313 (2019).","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"45404_CR24","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1097\/MJT.0000000000000779","volume":"27","author":"E Rayner-Hartley","year":"2020","unstructured":"Rayner-Hartley, E. et al. Ranolazine for Symptomatic Management of Microvascular Angina. Am. J. Ther. 27 (2), e151\u2013e158 (2020).","journal-title":"Am. J. Ther."},{"issue":"3","key":"45404_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0735-1097(02)02768-7","volume":"41","author":"MG Bourassa","year":"2003","unstructured":"Bourassa, M. G. et al. Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. J. Am. Coll. Cardiol. 41 (3), 351\u2013359 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"45404_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","volume":"97","author":"G Hasenfuss","year":"2008","unstructured":"Hasenfuss, G. & Maier, L. S. Mechanism of action of the new anti-ischemia drug ranolazine. Clin. Res. Cardiol. 97 (4), 222\u2013226 (2008).","journal-title":"Clin. Res. Cardiol."},{"issue":"2","key":"45404_CR27","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.21037\/qims-23-1029","volume":"14","author":"H Ling","year":"2024","unstructured":"Ling, H. et al. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant. Imaging Med. Surg. 14 (2), 1451\u20131465 (2024).","journal-title":"Quant. Imaging Med. Surg."},{"issue":"10","key":"45404_CR28","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1016\/j.clinthera.2019.08.008","volume":"41","author":"H Zhu","year":"2019","unstructured":"Zhu, H. et al. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin. Ther. 41 (10), 2137\u20132152e12 (2019).","journal-title":"Clin. Ther."},{"issue":"1","key":"45404_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.115.019768","volume":"133","author":"KP Alexander","year":"2016","unstructured":"Alexander, K. P. et al. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Circulation 133 (1), 39\u201347 (2016).","journal-title":"Circulation"},{"issue":"19","key":"45404_CR30","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","volume":"37","author":"CN Bairey Merz","year":"2016","unstructured":"Bairey Merz, C. N. et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur. Heart J. 37 (19), 1504\u20131513 (2016).","journal-title":"Eur. Heart J."},{"key":"45404_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2020.02.014","volume":"309","author":"VS Pargaonkar","year":"2020","unstructured":"Pargaonkar, V. S. et al. Effect of ranolazine on symptom and quality of life in patients with angina in the absence of obstructive coronary artery disease: A case control study. Int. J. Cardiol. 309, 8\u201313 (2020).","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"45404_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjcard.2004.09.025","volume":"95","author":"MF Rousseau","year":"2005","unstructured":"Rousseau, M. F. et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol. 95 (3), 311\u2013316 (2005).","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"45404_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3810\/pgm.2013.11.2711","volume":"125","author":"RA Kloner","year":"2013","unstructured":"Kloner, R. A., Hines, M. E. & Geunes-Boyer, S. Efficacy and safety of ranolazine in patients with chronic stable angina. Postgrad. Med. 125 (6), 43\u201352 (2013).","journal-title":"Postgrad. Med."},{"issue":"3","key":"45404_CR34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/echo.12674","volume":"32","author":"E Tagliamonte","year":"2015","unstructured":"Tagliamonte, E. et al. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography 32 (3), 516\u2013521 (2015).","journal-title":"Echocardiography"},{"key":"45404_CR35","doi-asserted-by":"crossref","unstructured":"Shah, N. R. et al. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J. Am. Heart Assoc., 6(5). (2017).","DOI":"10.1161\/JAHA.116.005027"},{"issue":"2","key":"45404_CR36","first-page":"66","volume":"9","author":"GL Murray","year":"2014","unstructured":"Murray, G. L. & Colombo, J. Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure. Heart Int. 9 (2), 66\u201373 (2014).","journal-title":"Heart Int."},{"issue":"5","key":"45404_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","volume":"45","author":"M Jerling","year":"2006","unstructured":"Jerling, M. Clinical pharmacokinetics of ranolazine. Clin. Pharmacokinet. 45 (5), 469\u2013491 (2006).","journal-title":"Clin. Pharmacokinet."},{"issue":"21","key":"45404_CR38","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","volume":"55","author":"S Sossalla","year":"2010","unstructured":"Sossalla, S. et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J. Am. Coll. Cardiol. 55 (21), 2330\u20132342 (2010).","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45404-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:35:55Z","timestamp":1780443355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45404"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45404-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all participants involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was conducted according to the guidelines of the.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"17073"}}